SlowBull
The Business Brief TUESDAY, 1 SEPTEMBER 2026
← All stories
Markets

Novartis says MS pill succeeds in two large studies

1 source ·1 article ·1h ago

Notably, Novartis revealed that remibrutinib wasn’t associated with the kind of liver-related side effects other BTK inhibitors like it have encountered.

Covered by 1 outlet

Biopharmadive 1

All coverage · 1 article

BioPharma Dive ·1h ago

Novartis says MS pill succeeds in two large studies

Notably, Novartis revealed that remibrutinib wasn’t associated with the kind of liver-related side effects other BTK inhibitors like it have encountered.